Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06977399

The Application Value of Spectral CT in the Accurate Staging of Liver Cancer

Spectral CT was used to prospectively collect medical images and clinical data related to liver cancer, evaluate the effect of image quality in the diagnosis of liver cancer, and evaluate the application value in the accurate staging of liver cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Liver Cancer Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Site

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment.
  • Age > 18 years.
  • Patients suspected of having liver cancer.
  • Patients who have signed the informed consent form.

Exclusion criteria

  • Severe cardiac, pulmonary, or renal insufficiency.
  • Allergy to iodine-based contrast agents.
  • Inability to cooperate with the CT examination.
  • Poor image quality of the Quark Spectral CT scan.
  • Women who are pregnant or breastfeeding.

Treatment and study plan

To explore the value of spectral CT in the diagnosis and treatment of liver cancer

Diagnostic Test

The CT scan is part of the standard treatment protocol.

Primary outcomes

  1. Pathological TNM staging

    Time frame: 1 day

    Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded

Study contacts

Contact information is provided by the study sponsor or research team.

Xumin Liu

CONTACT

[email protected]

+8615974863526

Zhenhui Li

CONTACT

[email protected]

+8613698736132

Sponsors and collaborators

Lead sponsor

Yunnan Cancer Hospital

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 18, 2025
Registry last updated
May 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.